AT‐101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
暂无分享,去创建一个
Kevin J. Thompson | Jennifer M. Carr | J. Carr | A. Chanan-Khan | A. Dispenzieri | Shaji K. Kumar | C. Reeder | S. Ansell | V. Roy | J. Mikhael | J. Foran | K. Chitta | A. Paulus | K. Miller | D. Personett | C. Rivera | Sharoon Akhtar
[1] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[2] F. Peale,et al. Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models , 2012 .
[3] I. Borrello. Can we change the disease biology of multiple myeloma? , 2012, Leukemia research.
[4] R. Neuwirth,et al. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma , 2012, Leukemia & lymphoma.
[5] A. Chanan-Khan,et al. Downregulation of BCL2 by AT‐101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner , 2012, British journal of haematology.
[6] N. Munshi,et al. Latest advances and current challenges in the treatment of multiple myeloma , 2012, Nature Reviews Clinical Oncology.
[7] M. Czuczman,et al. Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response , 2011, British journal of haematology.
[8] R. Clarke,et al. The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer , 2011, International journal of breast cancer.
[9] A. Chanan-Khan,et al. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia , 2011, Expert opinion on drug metabolism & toxicology.
[10] U. Völker,et al. Increased Expression of Bcl11b Leads to Chemoresistance Accompanied by G1 Accumulation , 2010, PloS one.
[11] A. Chanan-Khan,et al. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] John Calvin Reed,et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy , 2010, Cell Death and Disease.
[13] C. Hofmeister,et al. Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation. , 2009 .
[14] L. Leopold,et al. An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Jagannath,et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma , 2009, Leukemia & lymphoma.
[16] J. Nör,et al. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Y. Shidoji,et al. Enhanced Glucose Requirement in Human Hepatoma-derived HuH-7 Cells by Forced Expression of the bcl-2 Gene , 2008, Journal of clinical biochemistry and nutrition.
[18] Shaji K. Kumar,et al. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. , 2008, Experimental hematology.
[19] John Calvin Reed. Bcl-2-family proteins and hematologic malignancies: history and future prospects. , 2008, Blood.
[20] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[21] Jennifer L. Osborn,et al. Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.
[22] K. Pienta,et al. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. , 2007, Neoplasia.
[23] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[24] R. Korneluk,et al. The inhibitors of apoptosis (IAPs) as cancer targets , 2007, Apoptosis.
[25] R. Bociek,et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Donald Wlodkowic,et al. Larger than life: Mitochondria and the Bcl-2 family. , 2007, Leukemia research.
[27] J. Castro,et al. A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. , 2006 .
[28] T. Kipps,et al. AT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] T. Kipps,et al. AT 101, an Inhibitor of Bcl-2 Family Members Is Cytotoxic to a Heterogeneous Group of CLL Samples and Synergistic with Rituximab. , 2005 .
[30] Sanjeev Banerjee,et al. Nonpeptidic Small-Molecule Inhibitor of Bcl-2 and Bcl-XL, (−)-Gossypol, Enhances Biological Effect of Genistein Against BxPC-3 Human Pancreatic Cancer Cell Line , 2005, Pancreas.
[31] R. Bataille,et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival , 2005, Leukemia.
[32] D. Crouch,et al. Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3 , 2005, Molecular Cancer.
[33] Shaomeng Wang,et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. , 2005, Molecular cancer therapeutics.
[34] P. Richardson,et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application , 2005, British journal of haematology.
[35] Shaomeng Wang,et al. In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells , 2004, Clinical Cancer Research.
[36] A. Hagenbeek,et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma , 2004, Leukemia.
[37] T. Kuwana,et al. Bcl-2-family proteins and the role of mitochondria in apoptosis. , 2003, Current opinion in cell biology.
[38] John Calvin Reed,et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.
[39] Dajun Yang,et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. , 2003, Biochemical pharmacology.
[40] J. D. Vos,et al. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells , 2003, Oncogene.
[41] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[42] R. Bataille,et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.
[43] I. Gojo,et al. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.
[44] J. Sham,et al. Cytotoxic effect of gossypol on colon carcinoma cells. , 2000, Life sciences.
[45] R. Bataille,et al. Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells , 1999, British journal of haematology.
[46] B. Barlogie,et al. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.
[47] Y. Gazitt,et al. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. , 1998, International journal of oncology.
[48] W. Hu,et al. bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. , 1996, International journal of oncology.
[49] E. Tian,et al. bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines. , 1996, International journal of oncology.
[50] J. Magaud,et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.
[51] S. Korsmeyer,et al. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. , 1993, Cancer research.
[52] John Calvin Reed,et al. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. , 1992, Cancer research.
[53] L. Larsson,et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. , 1992, Blood.
[54] Paul C Boutros,et al. Systematic evaluation of medium-throughput mRNA abundance platforms. , 2013, RNA.
[55] R. Fonseca,et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.
[56] A. Strasser,et al. The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.
[57] W. Liang,et al. 9) TM4 Microarray Software Suite , 2006 .
[58] W. Liang,et al. TM4 microarray software suite. , 2006, Methods in enzymology.
[59] Shaomeng Wang,et al. In vitro Effects of the BH 3 Mimetic , ( )-Gossypol , on Head and Neck Squamous Cell Carcinoma Cells , 2004 .
[60] N. Munshi,et al. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. , 2003, Leukemia research.
[61] M. Fricová,et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 2002, Neoplasma.
[62] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.